P-glycoprotein inhibition of drug resistant cell lines by nanoparticles

References

• Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48–58
   PubMed Web of Science ®Google Scholar
• Thomas H, Coley HM. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting P-glycoprotein. Cancer Control 2003;10:159–65
   PubMedGoogle Scholar
• Nieto Montesinos R, Béduneau A, Pellequer Y, et al. Delivery of P-glycoprotein substrates using chemosensitizers and nanotechnology for selective and efficient therapeutic outcomes. J Control Release 2012;161:50–61
   PubMed Web of Science ®Google Scholar
• Rahman MA, Hussain A, Hussain MS, et al. Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system. Drug Dev Ind Pharm 2013;39:1–19
   PubMed Web of Science ®Google Scholar
• Wachsmann P, Lamprecht A. Ethylcellulose nanoparticles with bimodal size distribution as precursors for the production of very small nanoparticles. Drug Dev Ind Pharm 2014. [Epub ahead of print]. doi: 10.3109/03639045.2014.935393
   Google Scholar
• Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm Res 2008;25:500–11
   PubMed Web of Science ®Google Scholar
• Sosnik A. Reversal of multidrug resistance by the inhibition of ATP-binding cassette pumps employing “Generally Recognized As Safe” (GRAS) nanopharmaceuticals: a review. Adv Drug Deliv Rev 2013;65:1828–51
   PubMed Web of Science ®Google Scholar
• Seelig A, Gerebtzoff G. Enhancement of drug absorption by noncharged detergents through membrane and P-glycoprotein binding. Expert Opin Drug Metab Toxicol 2006;2:733–52
   PubMed Web of Science ®Google Scholar
• Hugger ED, Novak BL, Burton PS, et al. A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro. J Pharm Sci 2002;91:1991–2002
   PubMed Web of Science ®Google Scholar
• Cornaire G, Woodley J, Hermann P, et al. Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 2004;278:119–31
   PubMed Web of Science ®Google Scholar
• Hanke U, May K, Rozehnal V, et al. Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2). Eur J Pharm Biopharm 2010;76:260–8
   PubMed Web of Science ®Google Scholar
• Lamprecht A, Benoit J-P. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release 2006;112:208–13
   PubMed Web of Science ®Google Scholar
• Garcion E, Lamprecht A, Heurtault B, et al. A new generation of anticancer, drug-loaded, colloidal vectors reverses multidrug resistance in glioma and reduces tumor progression in rats. Mol Cancer Ther 2006;5:1710–22
   PubMed Web of Science ®Google Scholar
• Kang KW, Chun M-K, Kim O, et al. Doxorubicin-loaded solid lipid nanoparticles to overcome multidrug resistance in cancer therapy. Nanomedicine 2010;6:210–13
   PubMed Web of Science ®Google Scholar
• Ji X, Gao Y, Chen L, et al. Nanohybrid systems of non-ionic surfactant inserting liposomes loading paclitaxel for reversal of multidrug resistance. Int J Pharm 2012;422:390–7
   PubMed Web of Science ®Google Scholar
• Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrug-resistant tumors: current progress. Nanomedicine (Lond) 2010;5:597–615
   PubMed Web of Science ®Google Scholar
• Juvale K, Stefan K, Wiese M. Synthesis and biological evaluation of flavones and benzoflavones as inhibitors of BCRP/ABCG2. Eur J Med Chem 2013;67:115–26
   PubMed Web of Science ®Google Scholar
• Forster S, Thumser AE, Hood SR, et al. Characterization of rhodamine-123 as a tracer dye for use in in vitro drug transport assays. PLoS One 2012;7:e33253
   PubMed Web of Science ®Google Scholar
• Laine AL, Gravier J, Henry M, et al. Conventional versus stealth lipid nanoparticles: formulation and in vivo fate prediction through FRET monitoring. J Control Release 2014;188:1–8
   PubMed Web of Science ®Google Scholar
• Sun S, Lee D, Leung GKK. Chemoresistance in Glioma. In: Lee NP, Cheng CY, Luk JM, ed. New advances on disease biomarkers and molecular targets in biomedicine. New York (NY): Humana Press; 2013:243–70
   Google Scholar
• Zheng X, Cui DAI, Xu S, et al. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells. Int J Oncol 2010;37:307–15
   PubMed Web of Science ®Google Scholar
• Shono Y, Nishihara H, Matsuda Y, et al. Modulation of intestinal P-glycoprotein function by cremophor EL and other surfactants by an in vitro diffusion chamber method using the isolated rat intestinal membranes. J Pharm Sci 2004;93:877–85
   PubMed Web of Science ®Google Scholar
• Harush-Frenkel O, Debotton N, Benita S, et al. Targeting of nanoparticles to the clathrin-mediated endocytic pathway. Biochem Biophys Res Commun 2007;353:26–32
   PubMed Web of Science ®Google Scholar
• Sharma B, Peetla C, Adjei IM, et al. Selective biophysical interactions of surface modified nanoparticles with cancer cell lipids improve tumor targeting and gene therapy. Cancer Lett 2013;334:228–36
   PubMed Web of Science ®Google Scholar
• He Q, Gao Y, Zhang L, et al. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance. Biomaterials 2011;32:7711–20
   PubMed Web of Science ®Google Scholar
• Singh MS, Lamprecht A. Cargoing P-gp inhibitors via nanoparticle sensitizes tumor cells against doxorubicin. Int J Pharm 2015;478:745–52
   PubMed Web of Science ®Google Scholar
• Maupas C, Moulari B, Béduneau A, et al. Surfactant dependent toxicity of lipid nanocapsules in HaCaT cells. Int J Pharm 2011;411:136–41
   PubMed Web of Science ®Google Scholar